2015 Annual Meeting | 8HC.002 - Clinical Approach to Muscle Disease

Date Saturday 04/25/15

Time 08:00 AM - 12:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Half-Day Course

Director(s) Andrew Mammen, MD, PhD

Topic(s)

Learning Objectives Participants should be familiar with the differential diagnoses and how to evaluate and treat patients with different myopathies.

CME Available 3.75 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Recommended Audience Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
08:00 AM - 08:50 AM		Acquired Myopathies Andrew Mammen, MD, PhD
08:50 AM - 09:40 AM		Inclusion Body Myositis Steven A. Greenberg, MD
09:40 AM - 09:50 AM		Questions and Answers
09:50 AM - 10:05 AM		Break
10:05 AM - 10:55 AM		Muscular Dystrophies Matthew P. Wicklund, MD, FAAN
10:55 AM - 11:45 AM		The Distal Myopathies Ami K. Mankodi, MD, FAAN
11:45 AM - 12:00 PM		Questions and Answers

Faculty Disclosures
Andrew Mammen, MD, PhD	Dr. Mammen has received research support from National Institutes of Health. The institution of an immediate family member of Dr. Mammen has received research support from National Institutes of Health. Dr. Mammen has received intellectual property interests from a discovery or technology relating to health care.
Matthew P. Wicklund, MD, FAAN	Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus Therapeutics. Dr. Wicklund has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. Dr. Wicklund has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta Therapeutics. Dr. Wicklund has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Spark Therapeutics. Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ultragenyx. Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex Pharmaceuticals. The institution of Dr. Wicklund has received research support from Orphazyme. The institution of Dr. Wicklund has received research support from Muscular Dystrophy Association. The institution of Dr. Wicklund has received research support from Coalition to Cure Calpain 3. The institution of Dr. Wicklund has received research support from Sarepta Therapeutics. The institution of Dr. Wicklund has received research support from ML Bio. The institution of Dr. Wicklund has received research support from Alexion. The institution of Dr. Wicklund has received research support from Acceleron. The institution of Dr. Wicklund has received research support from Edgewise. The institution of Dr. Wicklund has received research support from Fulcrum. The institution of Dr. Wicklund has received research support from Roche-Genentech. The institution of Dr. Wicklund has received research support from Avidity. Dr. Wicklund has received research support from Harmony Bioscience.
Ami K. Mankodi, MD, FAAN	No disclosure on file
Steven A. Greenberg, MD	Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abcuro, Inc.. Dr. Greenberg has stock in Abcuro. Dr. Greenberg has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��